Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: A phase II study (CTONG-0803)

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 993-999

  Wu, Y L ^a   Zhou, C ^b   Cheng, Y ^c   Lu, S ^d   Chen, G Y ^e   Huang, C ^f   Huang, Y S ^a   Yan, H H ^a   Ren, S ^b   Liu, Y ^c   Yang, J J ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SHANGHAI PULMONARY HOSPITAL   (China)

^c Jilin Tumor Hospital   (China)

^d SHANGHAI CHEST HOSPITAL   (China)

^e HARBIN MEDICAL UNIVERSITY   (China)

^f Fujian Tumor Hospital   (China)

Author keywords

Brain metastases; Carcinoma; Erlotinib; Non small cell lung; Phase II clinical trial; Second line therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASYMPTOMATIC DISEASE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONJUNCTIVITIS; DIARRHEA; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FATIGUE; FEMALE; FUNCTIONAL STATUS; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPOCALCEMIA; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; MUTATIONAL ANALYSIS; NAIL; OPEN STUDY; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84875632711     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds529     Document Type: Article

References (37)

1. Lagerwaard FJ, Levendag PC, Nowak PJ et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999; 43: 795-803.
2. Srivastava G, Rana V, Wallace S et al. Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung cancer brain metastasis patients. J Thorac Oncol 2009; 4: 333-337.
3. Stuschke M, Eberhardt W, Pöttgen C et al. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: longterm follow-up and investigations of late neuropsychologic effects. J Clin Oncol 1999; 17: 2700-2709.
4. Ceresoli GL, Reni M, Chiesa G et al. Brain metastases in locally advanced non small cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer 2002; 95: 605-612.
5. Ricciardi S, de Marinis F. Multimodality management of non-small cell lung cancer patients with brain metastases. Curr Opin Oncol 2010; 22: 86-93.
6. Elaimy AL, Mackay AR, Lamoreaux WT et al. Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients. World J Surg Oncol 2011; 9: 69.
7. Pruitt AA. Medical management of patients with brain tumors. Curr Treat Options Neurol 2011; 13: 413-426.
8. Grimm SA. Treatment of brain metastases: chemotherapy. Curr Oncol Rep 2012; 14: 85-90.
9. Normanno N, Bianco C, De Luca A et al. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003; 10: 1-21.
10. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
11. Summary of Product Characteristics. Tarceva 25, 100 and 150mg film-coated tablets. http://www.medicines.org.uk/EMC/medicine/16781/SPC/Tarceva+25mg%2c+100mg+and+150mg+Film-Coated+Tablets/#INDICATIONS (11 April 2012, date last accessed).
12. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebocontrolled phase 3 study. Lancet Oncol 2010; 11: 521-529.
13. Pallis AG, Fennell DA, Szutowicz E et al. Biomarkers of clinical benefit for antiepidermal growth factor receptor agents in patients with non-small-cell lung cancer. Br J Cancer 2011; 105: 1-8.
14. Petrelli F, Borgonovo K, Cabiddu M et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell-lung cancer: a metaanalysis of 13 randomized trials. Clin Lung Cancer 2011; 13: 107-114.
15. Broniscer A, Panetta JC, O'Shaughnessy M et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 2007; 13: 1511-1515.
16. Togashi Y, Masago K, Fukudo M et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 2010; 5: 950-955.
17. Togashi Y, Masago K, Fukudo M et al.. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother Pharmacol 2011; 68: 1089-1092.
18. Porta R, Sánchez-Torres JM, Paz-Ares L et al.. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011; 37: 624-631.
19. Weber B, Winterdahl M, Memon A et al.. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 2011; 6: 1287-1289.
20. Therasse P, Arbuck SG, Eisenhauer EA et al.. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
21. Schwer AL, Gaspar LE. Update in the treatment of brain metastases from lung cancer. Clin Lung Cancer 2006; 8: 180-186.
22. Andrews DW, Scott CB, Sperduto PW et al.. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363: 1665-1672.
23. Aoyama H, Shirato H, Tago M et al.. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006; 295: 2483-2491.
24. Khuntia D, Brown P, Li J et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006; 24: 1295-1304.
25. Yi H, Kim H, Kim Y et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from nonsmall cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 2009; 65: 80-84.
26. Garassino MC, Martelli O, Bettini A et al.;1; TAILOR: a phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. J Clin Oncol 2012; 30(Suppl. 18, Pt II): (Abstr. LBA7501)
27. Garassino MC, Martelli O, Bettini A et al. TAILOR: a phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. J Clin Oncol 2012; 30(Suppl. 18, Pt II): (Abstr. LBA7501).
28. Wu Y, Kim J, Park K et al. Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of phase III, randomized SATURN trial. Lung Cancer 2012; 77: 339-345.
29. Bai H, Han B. The effectiveness of erlotinib against brain metastases in nonsmall-cell-lung cancer patients. Am J Clin Oncol 2012; [epub ahead of print 2 March 2012] doi:10.1097/COC.0b013e3182438c91.
30. Clarke JL, Pao W, Wu N et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010; 99: 283-286.
31. Grommes C, Oxnard G, Kris M et al. 'Pulsatile' high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011; 13: 1364-1369.
32. Ceresoli GL, Cappuzzo F, Gregorc V et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004; 15: 1042-1047.
33. Hotta K, Kiura K, Ueoka H et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 46: 255-261.
34. Namba Y, Kijima T, Yokota S et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 2004; 6: 123-128.
35. Chiu CH, Tsai CM, Chen YM et al. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005; 47: 129-138.
36. Wu C, Li YL, Wang ZM et al. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 2007; 57: 359-364.
37. Kim ST, Uhm JE, Lee J et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 2012; 75: 82-88.